Evidence map›Paper›PMID 26763999›Full record

ArticleJournal of virology2016

Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.

Shilpa Patil, Rajesh Kumar, Suprit Deshpande, Sweety Samal, Tripti Shrivastava, Saikat Boliar, Manish Bansal, Nakul Kumar Chaudhary, Aylur K Srikrishnan, Kailapuri G Murugavel and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Shilpa PatilHIV Vaccine Translational Research Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
Rajesh KumarHIV Vaccine Translational Research Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
Suprit DeshpandeHIV Vaccine Translational Research Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
Sweety SamalHIV Vaccine Translational Research Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
Tripti ShrivastavaHIV Vaccine Translational Research Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
Saikat BoliarHIV Vaccine Translational Research Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
Manish BansalHIV Vaccine Translational Research Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
Nakul Kumar ChaudharyHIV Vaccine Translational Research Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
Aylur K SrikrishnanY. R. Gaitonde Research and Care Center, Chennai, India.
Kailapuri G MurugavelY. R. Gaitonde Research and Care Center, Chennai, India.
Suniti SolomonY. R. Gaitonde Research and Care Center, Chennai, India.
Melissa SimekInternational AIDS Vaccine Initiative, New York, New York, USA.
Wayne C KoffInternational AIDS Vaccine Initiative, New York, New York, USA.
Rajat GoyalInternational AIDS Vaccine Initiative, New York, New York, USA.
Bimal K ChakrabartiHIV Vaccine Translational Research Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India International AIDS Vaccine Initiative, New York, New York, USA.
Jayanta BhattacharyaHIV Vaccine Translational Research Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India International AIDS Vaccine Initiative, New York, New York, USA JBhattacharya@iavi.org.
Translational Health Science and Technology Institute · INInternational AIDS Vaccine Initiative · USYR Gaitonde Centre for AIDS Research and Education · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledBroadly neutralizing antibodies isolated from infected patients who are elite neutralizers have identified targets on HIV-1 envelope (Env) glycoprotein that are vulnerable to antibody neutralization; however, it is not known whether infection established by the majority of the circulating clade C strains in Indian patients elicit neutralizing antibody responses against any of the known targets. In the present study, we examined the specificity of a broad and potent cross-neutralizing plasma obtained from an Indian elite neutralizer infected with HIV-1 clade C. This plasma neutralized 53/57 (93%) HIV pseudoviruses prepared with Env from distinct HIV clades of different geographical origins. Mapping studies using gp120 core protein, single-residue knockout mutants, and chimeric viruses revealed that G37080 broadly cross-neutralizing (BCN) plasma lacks specificities to the CD4 binding site, gp41 membrane-proximal external region, N160 and N332 glycans, and R166 and K169 in the V1-V3 region and are known predominant targets for BCN antibodies. Depletion of G37080 plasma with soluble trimeric BG505-SOSIP.664 Env (but with neither monomeric gp120 nor clade C membrane-proximal external region peptides) resulted in significant reduction of virus neutralization, suggesting that G37080 BCN antibodies mainly target epitopes on cleaved trimeric Env. Further examination of autologous circulating Envs revealed the association of mutation of residues in the V1 loop that contributed to neutralization resistance. In summary, we report the identification of plasma antibodies from a clade C-infected elite neutralizer that mediate neutralization breadth via epitopes on trimeric gp120 not yet reported and confer autologous neutralization escape via mutation of residues in the V1 loop. IMPORTANCE: A preventive vaccine to protect against HIV-1 is urgently needed. HIV-1 envelope glycoproteins are targets of neutralizing antibodies and represent a key component for immunogen design. The mapping of epitopes on viral envelopes vulnerable to immune evasion will aid in defining targets of vaccine immunogens. We identified novel conformational epitopes on the viral envelope targeted by broadly cross-neutralizing antibodies elicited in natural infection in an elite neutralizer infected with HIV-1 clade C. Our data extend our knowledge on neutralizing epitopes associated with virus escape and potentially contribute to immunogen design and antibody-based prophylactic therapy.

Indexed as

AIDS VaccinesAntibodies, NeutralizingCell Lineenv Gene Products, Human Immunodeficiency VirusEpitope MappingEpitopesHEK293 CellsHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHumansImmune EvasionIndiaAIDS VaccinesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusEpitopesgp120 protein, Human immunodeficiency virus 1gp140 envelope protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp120

Identifiers

PMID26763999
PMCPMC4794693
OpenAlexW2239363967

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.